TRUE NORTH NEUROLOGY CURRENT CLINICAL TRIALS
MIGRAINE CLINICAL TRIALS
Lundbeck Protocol 19356A: Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of IV Eptinezumab in Adolescents (12-17 years) for the Preventive Treatment of Chronic Migraine
Lundbeck Protocol 19357A: Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Eptinezumab in Pediatric patients (6 to 17 years) for the Preventive Treatment of Episodic Migraine
Lundbeck Protocol 19379A: Long-term, Open-Label (Dose-Blinded), Extension Study of Eptinezumab in Children and Adolescents with Chronic or Episodic Migraine
Pfizer Protocol BHV3000-311: Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of Rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age
Pfizer Protocol BHV3000-312: Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of Rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < 18 years of age
Pfizer Protocol C5301023: A Phase 1, Multicenter, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Zavegepant in Children 6 to Less Than 12 Years of Age with History of Migraine- In start-up process- expected start July
AbbVie Protocol M23-714: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the
Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension
Merz Protocol M602011084: A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of chronic migraine
Merz Protocol M602011085: A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of Xeomin® injections for the prevention of episodic migraine.
AbbVie Protocol P25-590: Phases: Prodrome in the Real World: Assessing Ubrogepant Acute Use
Lundbeck 20668A: Interventional, open-label trial, investigating the effectiveness of Eptinezumab in participants with migraine and previous inadequate response to CGRP-targeting therapies
Kallyope Protocol K-304 P005: A Multicenter, Long-Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Protocol K-304 P003: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of Elismetrep (K-304) in the Acute Treatment of Migraine
MULTIPLE SCLEROSIS CLINICAL TRIALS
Novartis Protocol COMB157Q12301: An open-label, randomized, parallel group, non-inferiority study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of a new maintenance dosing regimen of ofatumumab, followed by extended treatment in participants with relapsing multiple sclerosis- expected start June
Novartis Protocol CLOU064C12304: A Randomized, Double Blind, Double Dummy, Placebo Group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants with Relapsing Multiple Sclerosis, Followed by Extended Treatment with Open-Label Remibrutinib
MOVEMENT DISORDERS CLINICAL TRIALS
AbbVie Protocol M25-850: A Phase 2b/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AGN 151607 DP (USAN: gemibotuliniumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults
OTHER PAIN DISORDERS
Theranica Protocol TCH-200: Open label use of Nerivio for management of Temporomandibular disorders.
A Retrospective Community Based Study Evaluating Disability in Migraine Patients Treated with Erenumab-aoee. American Headache Society 61st Annual Scientific Meeting. Philadelphia, PA July 11-14, 2019
A Two-Year Retrospective Review: Community-Based Outpatient Infusion Center Acute Treatment of Refractory Migraine. American Headache Society 58th Annual Scientific Meeting, San Diego, CA, June 10, 2016.
Chart Review of Lymphocyte Reconstitution Among MS Patients After Discontinuation of Dimethyl Fumarate American Academy of Neurology, 2021 Virtual Annual Meeting, April 17-22, 2021
Comparison of Skin Cell Immunity in Patients Receiving Treatment with Gilenya (fingolimod) and Healthy Controls. 7th Joint ECTRIMS - ACTRIMS Meeting Paris, France, October 25-28, 2017
Is Chronic Migraine More Common in the Multiple Sclerosis Population? American Headache Society 59th Annual Scientific Meeting. Boston, MA June 9, 2017
Sustained efficacy of botulinum toxin type-A (BTXA) on migraine-related disability over 3 treatment cycles in a community-based setting. Cephalalgia, 29 (Suppl 1) (2009) 145.
